Strong mRNA expression and siRNA silencing across multiple organs demonstrate the superior performance and reliability of RJH’s delivery technology.
Robust Multi-Organ mRNA Expression
mRNA-Fect Ultra enabled robust in vivo luciferase mRNA expression following intraperitoneal administration. Whole-animal images (left) and organ-level luminescence quantitation (right) show high, consistent expression across key tissues.
Efficient In Vivo siRNA Delivery Across Multiple Tissue
Quantification of siRNA levels in tissues after systemic delivery with RJH reagents. siRNA copy numbers per ng of total RNA were measured in select tissues using ddPCR 12 days after initial injection. High siRNA delivery efficiency was observed across multiple tissues, indicating efficacy delivery.
Powerful siRNA Effect
Subcutaneous and intraperitoneal administration of Prime-Fect/siRNA formulations led to marked inhibition of breast cancer tumor growth in mice, confirming the potent in vivo efficacy of RJH’s delivery technology.
Driving Strong mRNA Expression & siRNA Silencing In Vivo
Achieving both potent mRNA expression and effective siRNA-mediated gene silencing across multiple tissues highlights the potential of advanced RNA delivery technologies. By enabling robust expression of therapeutic mRNA while concurrently knocking down target genes with siRNA, researchers can explore functional genomics, disease modulation, and therapeutic strategies with greater precision. This dual‑action capability leans on optimized delivery platforms to ensure RNA stability, cellular uptake, and activity in target organs, addressing key challenges in RNA therapeutic development.
At RJH Biosciences, our tailored delivery solutions are engineered to support strong in vivo mRNA expression and reliable siRNA silencing across diverse experimental models, helping you achieve meaningful biological insights and accelerate your research outcomes.
